Danaher Co. (NYSE:DHR) Stock Holdings Lessened by Vaughan Nelson Investment Management L.P.

Vaughan Nelson Investment Management L.P. lessened its stake in Danaher Co. (NYSE:DHR - Free Report) by 4.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 591,571 shares of the conglomerate's stock after selling 27,815 shares during the period. Danaher accounts for approximately 1.3% of Vaughan Nelson Investment Management L.P.'s investment portfolio, making the stock its 24th largest holding. Vaughan Nelson Investment Management L.P. owned about 0.08% of Danaher worth $135,796,000 at the end of the most recent reporting period.

Several other hedge funds have also modified their holdings of DHR. Wedge Capital Management L L P NC lifted its holdings in Danaher by 3.2% in the third quarter. Wedge Capital Management L L P NC now owns 1,231 shares of the conglomerate's stock valued at $342,000 after acquiring an additional 38 shares during the period. Meridian Financial Partners LLC lifted its stake in shares of Danaher by 4.4% in the third quarter. Meridian Financial Partners LLC now owns 957 shares of the conglomerate's stock valued at $266,000 after purchasing an additional 40 shares during the period. Kovack Advisors Inc. boosted its holdings in Danaher by 3.4% during the third quarter. Kovack Advisors Inc. now owns 1,243 shares of the conglomerate's stock worth $346,000 after buying an additional 41 shares in the last quarter. Well Done LLC grew its position in Danaher by 1.2% during the third quarter. Well Done LLC now owns 3,551 shares of the conglomerate's stock worth $987,000 after buying an additional 42 shares during the period. Finally, Waypoint Capital Advisors LLC lifted its position in shares of Danaher by 0.9% during the 3rd quarter. Waypoint Capital Advisors LLC now owns 4,520 shares of the conglomerate's stock valued at $1,257,000 after acquiring an additional 42 shares during the period. 79.05% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Danaher Trading Up 0.3 %

DHR stock traded up $0.60 during midday trading on Wednesday, reaching $202.22. 7,207,744 shares of the company's stock traded hands, compared to its average volume of 4,373,626. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.40 and a quick ratio of 1.05. Danaher Co. has a fifty-two week low of $196.80 and a fifty-two week high of $281.70. The business has a 50-day moving average price of $231.17 and a two-hundred day moving average price of $250.62. The company has a market capitalization of $146.06 billion, a P/E ratio of 38.30, a PEG ratio of 2.68 and a beta of 0.83.

Danaher (NYSE:DHR - Get Free Report) last announced its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 earnings per share for the quarter, hitting analysts' consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.82%. During the same quarter in the previous year, the business posted $2.09 earnings per share. Equities research analysts forecast that Danaher Co. will post 7.67 EPS for the current fiscal year.

Danaher Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Friday, January 31st. Investors of record on Friday, December 27th were issued a dividend of $0.27 per share. The ex-dividend date of this dividend was Friday, December 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.53%. Danaher's payout ratio is currently 20.45%.

Insider Buying and Selling

In other news, SVP Brian W. Ellis sold 5,700 shares of the firm's stock in a transaction dated Thursday, January 30th. The stock was sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the completion of the sale, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This trade represents a 21.98 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 11.10% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several research firms recently weighed in on DHR. KeyCorp raised their price objective on Danaher from $290.00 to $310.00 and gave the company an "overweight" rating in a research note on Wednesday, October 23rd. Royal Bank of Canada restated an "outperform" rating and issued a $277.00 price target (down previously from $299.00) on shares of Danaher in a research report on Thursday, January 30th. Stephens reiterated an "overweight" rating and issued a $315.00 price objective on shares of Danaher in a research report on Wednesday, October 23rd. Wolfe Research upgraded shares of Danaher from a "peer perform" rating to an "outperform" rating and set a $285.00 target price for the company in a report on Thursday, October 31st. Finally, Bank of America raised shares of Danaher from a "neutral" rating to a "buy" rating and set a $290.00 price target on the stock in a report on Friday, December 13th. Seven analysts have rated the stock with a hold rating and fifteen have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average target price of $278.00.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.